Who are Esmolol Injection [Brevibloc]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Onoact, Betaxon, Genesa, Zebeta, Levadil, Optipranolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/esmolol-injection-brevibloc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Esmolol Injection [Brevibloc] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Esmolol Injection [Brevibloc] (Esmolol Injection [Brevibloc]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-1 selective adrenergic antagonist. Area: Cardiovascular.

phase 3 Beta-1 selective adrenergic antagonist Beta-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Esmolol Injection [Brevibloc] (Esmolol Injection [Brevibloc]) — Consorcio Centro de Investigación Biomédica en Red (CIBER). Esmolol is a selective beta-1 adrenergic receptor antagonist that rapidly blocks sympathetic stimulation of the heart, reducing heart rate and blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Esmolol Injection [Brevibloc] TARGET	Esmolol Injection [Brevibloc]	Consorcio Centro de Investigación Biomédica en Red (CIBER)	phase 3	Beta-1 selective adrenergic antagonist	Beta-1 adrenergic receptor
Onoact	LANDIOLOL	Aop Hlth Us	marketed	landiolol	Beta-1 adrenergic receptor	2024-01-01
Betaxon	LEVOBETAXOLOL	Alcon Pharms Ltd	marketed	levobetaxolol	Beta-1 adrenergic receptor	2000-01-01
Genesa	ARBUTAMINE		marketed	arbutamine	Beta-1 adrenergic receptor	1997-01-01
Zebeta	BISOPROLOL	Teva	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1992-01-01
Levadil	DILEVALOL		marketed	dilevalol	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor	1990-01-01
Optipranolol	METIPRANOLOL	Bausch Health	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-1 selective adrenergic antagonist class)

Consorcio Centro de Investigación Biomédica en Red (CIBER) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Esmolol Injection [Brevibloc] — Competitive Intelligence Brief. https://druglandscape.com/ci/esmolol-injection-brevibloc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab